Literature DB >> 25656443

Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus.

Rosa Bou1, Alfredo Adán, Fátima Borrás, Beatriz Bravo, Inmaculada Calvo, Jaime De Inocencio, Jesús Díaz, Julia Escudero, Alex Fonollosa, Carmen García de Vicuña, Victoria Hernández, Rosa Merino, Jesús Peralta, María-Jesús Rúa, Pilar Tejada, Jordi Antón.   

Abstract

Uveitis associated with juvenile idiopathic arthritis (JIA) typically involves the anterior chamber segment, follows an indolent chronic course, and presents a high rate of uveitic complications and a worse outcome as compared to other aetiologies of uveitis. Disease assessment, treatment, and outcome measures have not been standardized. Collaboration between pediatric rheumatologists and ophthalmologists is critical for effective management and prevention of morbidity, impaired vision, and irreparable visual loss. Although the Standardization of Uveitis Nomenclature Working Group recommendations have been a great advance to help clinicians to improve consistency in grading and reporting data, difficulties arise at the time of deciding the best treatment approach in the individual patient in routine daily practice. For this reason, recommendations for a systematized control and treatment strategies according to clinical characteristics and disease severity in children with JIA-related uveitis were developed by a panel of experts with special interest in uveitis associated with JIA. A clinical management algorithm organized in a stepwise regimen is here presented.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25656443     DOI: 10.1007/s00296-015-3231-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  41 in total

1.  Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases.

Authors:  C C Mok; D van der Kleij; G J Wolbink
Journal:  Clin Rheumatol       Date:  2013-07-26       Impact factor: 2.980

2.  Comparison of topical steroids for acute anterior uveitis.

Authors:  S S Samudre; F A Lattanzio; P B Williams; J D Sheppard
Journal:  J Ocul Pharmacol Ther       Date:  2004-12       Impact factor: 2.671

3.  Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis.

Authors:  Paolo Ferrante; Andrew Ramsey; Catey Bunce; Susan Lightman
Journal:  Clin Exp Ophthalmol       Date:  2004-12       Impact factor: 4.207

4.  Course, complications, and outcome of juvenile arthritis-related uveitis.

Authors:  Kourosh Sabri; Rotraud K Saurenmann; Earl D Silverman; Alex V Levin
Journal:  J AAPOS       Date:  2008-09-12       Impact factor: 1.220

5.  Pharmacokinetics of topically applied cyclopentolate HCl and tropicamide.

Authors:  J V Lovasik
Journal:  Am J Optom Physiol Opt       Date:  1986-10

6.  Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.

Authors:  Friederike Mackensen; Carsten Heinz; Matthias D Becker; Arnd Heiligenhaus
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

7.  Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.

Authors:  Alfredo Adán; Laura Pelegrín; Amanda Rey; Victor Llorenç; Marina Mesquida; Blanca Molins; José Ríos; Johannes Keller
Journal:  Retina       Date:  2013 Jul-Aug       Impact factor: 4.256

8.  Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.

Authors:  Rene A Cervantes-Castañeda; Gian Paolo Giuliari; Michael J Gallagher; Taygan Yilmaz; Rebecca E MacDonell; Karina Quinones; Charles S Foster
Journal:  Eur J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 2.597

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  Occurrence and management of ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis: An observational series of 104 patients.

Authors:  Kaisu Kotaniemi; Kristiina Sihto-Kauppi
Journal:  Clin Ophthalmol       Date:  2007-12
View more
  29 in total

1.  Adalimumab for the treatment of refractory noninfectious paediatric uveitis.

Authors:  Alicia Muñoz-Gallego; Estefanía Barral; Eugenia Enríquez; Pilar Tejada; Ana Barceló; Jaime de Inocencio
Journal:  Int Ophthalmol       Date:  2016-07-18       Impact factor: 2.031

Review 2.  IL-6 blockade in the management of non-infectious uveitis.

Authors:  Giuseppe Lopalco; Claudia Fabiani; Jurgen Sota; Orso Maria Lucherini; Gian Marco Tosi; Bruno Frediani; Florenzo Iannone; Mauro Galeazzi; Rossella Franceschini; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-05-20       Impact factor: 2.980

Review 3.  Uveitis in children.

Authors:  Sheila T Angeles-Han; Consuelo Egla Rabinovich
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

4.  An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.

Authors:  Arjun B Sood; Sheila T Angeles-Han
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-01-29

5.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Authors:  Sheila T Angeles-Han; Sarah Ringold; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Gary N Holland; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; H Nida Sen; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04-25       Impact factor: 4.794

6.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Authors:  Sheila T Angeles-Han; Sarah Ringold; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Gary N Holland; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; H Nida Sen; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Rheumatol       Date:  2019-04-25       Impact factor: 10.995

7.  [Uveitis in juvenile idiopathic arthritis].

Authors:  I Foeldvari; K Walscheid; A Heiligenhaus
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

8.  Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis.

Authors:  Sheila T Angeles-Han; Mindy S Lo; Lauren A Henderson; Melissa A Lerman; Leslie Abramson; Ashley M Cooper; Miriam F Parsa; Lawrence S Zemel; Tova Ronis; Timothy Beukelman; Erika Cox; H Nida Sen; Gary N Holland; Hermine I Brunner; Andrew Lasky; C Egla Rabinovich
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04       Impact factor: 4.794

Review 9.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

10.  Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.

Authors:  Courtney McCracken; Steven Yeh; Kirsten Jenkins; Curtis Travers; Daneka Stryker; Steven Tommasello; Kelly A Rouster-Stevens; Scott R Lambert; Sampath Prahalad; Carolyn Drews-Botsch; Sheila T Angeles-Han
Journal:  Eye (Lond)       Date:  2018-11-28       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.